Myeloid-derived suppressor cells in COVID-19: A review.
Clin Immunol
; 238: 109024, 2022 05.
Article
in English
| MEDLINE | ID: covidwho-1803762
ABSTRACT
Coronavirus disease 2019 (COVID-19) is a potentially life-threatening infection characterized by excessive inflammation, coagulation disorders and organ damage. A dysregulated myeloid cell compartment is one of the most striking immunopathologic signatures of this newly emerged infection. A growing number of studies are reporting on the expansion of myeloid cells with immunoregulatory activities in the periphery and airways of COVID-19 patients. These cells share phenotypic and functional similarities with myeloid-derived suppressor cells (MDSCs), which were first described in cancer patients. MDSCs are a heterogeneous population of pathologically activated myeloid cells that exert immunosuppressive activities against mainly effector T cells. The increased frequency of these cells in COVID-19 patients suggests that they are involved in immune regulation during this infection. In this article, we review the current findings on MDSCs in COVID-19 and discuss the complex role of these cells in the immunopathology of COVID-19.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Myeloid-Derived Suppressor Cells
/
COVID-19
Limits:
Humans
Language:
English
Journal:
Clin Immunol
Journal subject:
Allergy and Immunology
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS